The CD28/CTLA-4 ligands, B7-1 (CD80) and B7-2 (CD86), provide a co-stimulatory signal necessary for optimal T cell activation. We have examined the effect of blocking B7-1 and B7-2 in an in vitro system using ovalbumin-specific T cells from ap* TCR-transgenic mice. This system allowed us to examine the interaction of B7 co-stimulators on physiologic antigen-presenting cells (APC) with antigen-specific T helper precursor (T h p) cells. We report that blocking T h p/B7-1 or B7-2 interactions in a primary response differentially affects the cytokine profile observed in a secondary stimulation, even in the absence of additional anti-B7 antibody. Engagement of B7-2 in the primary stimulation was found to be essential for production of the T h 2 cytokine, IL-4, but not the T h 1 cytokines, IL-2 and IFN-y, in a secondary stimulation. Conversely, inclusion of the anti-B7-1 mAb in cultures using highly purified naive T cells increased levels of IL-4 and significantly depressed levels of IFN-y, upon re-stimulation. The effect of the anti-B7-2 mAb in reducing IL-4 production could be overcome by the addition of recombinant IL-4 in the primary stimulation. The effects of the anti-B7-2 mAb appear to be due to blocking and not cross-linking, as F(ab) fragments mimicked the intact antibody. Taken together, our data demonstrate that the interaction between T h p and B7-2 favors the development of T h 2 cells.
Introduction
Signaling through the TCR complex alone is not sufficient for the full activation of resting CD4 + T cells. An additional, antigen-non-specific, interaction is necessary (1) (2) (3) . This signal, distinct from that generated by the TCR, is referred to as co-stimulation. The B7 co-stimulatory pathway, likely the most important second signal defined to date, involves at least two molecules, B7-1 (CD80) (4) and B7-2 (CD86) (5) (6) (7) (8) , both of which interact with their counter-receptors, CD28 and CTLA-4, on T cells (6, 8, 9) . CD28, which is constitutively present on most CD4 + and CD8 + T cells, is thought to transmit a positive signal (10, 11) . It has been shown that blockade of signaling through CD28 results in severe defects in T cell activation and, in some cases, long-term hyporesponsiveness or anergy (9, (11) (12) (13) (14) (15) . CD28-deficient mice exhibit diminished T cell proliferation in response to allogeneic APC, anti-CD3 mAb and mitogens (16, 17) . In contrast, CTLA-4 appears to transmit a down-regulatory or apoptotic signal (17) (18) (19) (20) . Until recently, the expression of B7 molecules was thought to be restricted to the antigen-presenting cell (e.g. macrophages, dendritic cells or activated B cells) and the expression of their ligands, CD28/CTLA-4, restricted to the T cell. However, B7 molecules have now been found on T cells (21) and CTLA-4 antigens on activated B cells (22) , creating a highly complex system.
It was initially suggested that the two B7 molecules were functionally identical. Multiple in vitro studies with B7 transfectants have demonstrated that both ligands are capable of co-stimulating T cell proliferation as well as IL-2 production (23) (24) (25) (26) . However, more recent evidence suggests that they may have non-overlapping functions. For example, B7-1 is superior to B7-2 in the co-stimulation of cytotoxic T lymphocyte activity (27) and the induction of T cell-mediated antileukemia immunity (28) . Further, the tissue distribution as well as kinetics and regulation of induction of the B7 molecules differ (6, (29) (30) (31) . While B7-1 and B7-2 share the same receptors, CD28 and CTLA-4, they interact with distinct sites on these receptors and have different kinetics of binding to them (32, 33) . Thus, it is possible that the ligation of CD28/CTLA-4 by B7-1 and B7-2 results in the generation of different intracellular signals.
Indeed, a number of studies have suggested that the two B7 molecules might have differential effects on T h cell development. We have shown that in experimental allergic encephalomyelitis (EAE), a murine model of multiple sclerosis, anti-B7-1 mAb reduced the incidence of disease while anti-B7-2 mAb increased disease severity (34) . These antibodies appeared to exert their effects by altering cytokine profiles. Administration of the anti-B7-1 mAb resulted in a decrease in PLP-specific, IFN-y-producing (T h 1) cells, and an increase in IL-4/IL-10-producing (T h 2) cells. Recently, similar findings on the effect of anti-B7 mAb in actively induced EAE have been reported by Racke era/. (35) . Interestingly, in a distinct murine disease model of human autoimmune diabetes, the non-obese diabetic (NOD) mouse, anti-B7-1 and -2 mAb had the reverse effect on the development of disease (36) . In that system, CTLA-4-lg and anti-B7-2 mAb treatment prevented the development of insulin-dependent diabetes mellitus whereas the anti-B7-1 mAb exacerbated disease. These studies suggest that the interaction of the T helper precursor (T h p) cells with B7-1 and B7-2 may influence T h cell differentiation.
The above studies have been done in vivo where it is difficult to isolate and study T h p/APC interactions. In fact, the seemingly contradictory effect of anti-B7 mAb administration in two T h 1 -mediated disease models (EAE and NOD) suggests that the site of activation and/or type of APC involved might influence outcome. To further explore the interaction of the B7-1 and B7-2 molecules with CD4 + T cells we chose an in vitro system using ovalbumin (OVA)-specific T cells from D011.10 TCR-transgenic mice. This system allowed us to evaluate the response of T h p cells to nominal antigen presented by physiologic APC in a carefully controlled setting. Here we report that administration of anti-B7-1 or B7-2 mAb in a primary stimulation differentially affects cytokine production. Our experiments suggest that the T h p/B7-2 interaction is essential for the development of T h 2 cells while T h 1 cells can utilize either B7-1 or B7-2 co-stimulators to progress along a T h 1 pathway.
Methods

Mice
BALB/c mice (6-8 weeks old) were obtained from Taconic Farms (Germantown, NY) or the Jackson Laboratory (Bar Harbor, ME). Mice transgenic for the DO11.10 a|3 TCR were generously provided by Dr D. Loh (Washington University, St Louis, MO) and maintained at the Harvard School of Public Health (Boston, MA). Mice were housed in sterilized microisolator cages, fed autoclaved food and water, and handled in laminar airflow hoods. Expression of the DO11.10 transgene was evaluated by PCR analysis of tail DNA. All mice were used at 6-14 weeks of age.
Culture media and reagents
Cultures were maintained in RPMI 1640 (Gibco/BRL, Gaithersburg, MD) supplemented with 10% FBS (HyClone, Logan, UT), 2 mM L-glutamine, 100 U/ml penicillin, 100 ng/ ml streptomycin, 5X10" 5 M 2-mercaptoethanol and 10 mM HEPES (Mediatech, Herndon, VA). Cultures undergoing repetitive stimulations were rested in the above preparation with addition of 100 ng/ml gentamycin and 1-5% human T-stim (Collaborative Biomedical Products, Bedford, MA). Lipopolysaccharide (LPS 0111 :B4) and OVA were purchased from Sigma (St Louis, MO).
Antibodies and recombinant proteins
Purified anti-B7-1 (1G10) and anti-B7-2 (2D10) antibodies were the kind gift of Dr N. Nabavi (University of South Carolina, Charleston, SC). The antibodies are of the rat lgG2a and lgG2b isotypes respectively. An additional anti-B7-1 antibody, 16-10A1 was provided by Dr H. Reiser (Dana Farber Cancer Institute, Boston, MA). This hamster antibody was purified from culture supernatant over a Protein A-Sepharose column. A F(ab) fragment of the 16-10A1 mAb was generously provided by Dr J. Bluestone (University of Chicago, Chicago, IL). A second anti-B7-2 mAb, GL1, was purchased from PharMingen (San Diego, CA). The F(ab) fragment of this antibody was a gift of Dr C. June (Naval Medical Research Institute, Bethesda, MD). Rat and hamster isotype controls were obtained from Cappel (Durham, NC). CRL 1741 (antiras p21 protein) and HB152 (xBw6) were purchased from ATCC (Rockville, MD). These cell lines produce rat antibodies of the lgG2a and lgG2b isotypes respectively, which were purified from tissue culture supernatant over a Protein A column Neither antibody displayed reactivity with the BALB/c splenocyte population by FACS analysis.
Antibodies utilized for immunofluorescence analysis or sorting studies were as follows: anti-CD3e (145-2C11), anti-CD4 (RM4-4), anti-CD8a (53-6.7), anti-CD45R/B220 (RA3-6B2), anti-CD44 (IM7), anti-CD62L/L-selectin (MEL-14), anti-CD45RB (23G2), anti-Mac-1o/CD11b (M1/70), anti-CD11c (HL3), anti-B7-1(16-10A1) and anti-B7-2 (GL1). All the above antibodies were either directly phycoerythrin (PE)-or FITCconjugated (PharMingen, San Diego, CA). The rat anti-mouse FcRylI/Ill mAb (2.4G2) was used to block non-specific binding during FACS analysis.
Murine rlL-4 was purchased from Genzyme (Boston, MA). Murine rlL-2 was obtained from Collaborative Biomedical Products. Murine rlL-12 was a gift of Dr M. Gately (HoffmannLa Roche, Nutley, NJ).
Lymphokine assays
Quantitation of cytokines produced by cultured cells was done by ELISA. Culture supernatants were collected 40-48 h after addition of antigen unless otherwise indicated. Analysis for IL-2, IL-4, granulocyte macrophage colony stimulating factor (GM-CSF), IFN-y, tumor necrosis factor (TNF)-a and IL-10 was essentially as described (34) with the exception that detection was performed with avidin-alkaline phosphatase and substrate, />nitrophenyl phosphate (Sigma) and read at 405 nm. An antibody capture bioassay for IL-12 was performed as described (37) . Anti-IL-12 antibody (5C3) was the gift of Dr M. Gately (Hoffman-LaRoche, Nutley, NJ). All samples were performed in duplicate. Cells were then depleted of residual APC by adherence to plastic at 37°C for 2-4 h. T cells purified in this manner were routinely 90% CD4
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+ by flow cytometric analysis and failed to proliferate or produce cytokines when cultured with OVA in the absence of added APC.
Further separation of naive CD4 + T cells from previously activated cells was performed where indicated by cell sorting for CD45RB expression. The total CD4 + T cell population was double-labeled with CD4-PE and CD45RB-FITC. The CD45RB high population was collected as naive T cells.
T-depleted spleen populations from non-transgenic BALB/c mice were produced through (a) depletion of T cells by incubation in culture supernatants containing anti-Thy-1.2 (AT83A), anti-CD4 (GK1.5) and anti-CD8 (TIB211) mAb followed by complement and density gradient centrifugation as above. Recovered cells were routinely 90% B220 + by FACS with <2% contaminating CD3 + cells. Where indicated, T-depleted splenocytes were activated by culture in 50 |j.g/ ml LPS for 48 h. At this time they were irradiated (1000 rad) and washed extensively.
Splenic adherent cells were prepared from non-transgenic BALB/c mice. A single-cell suspension of splenocytes from six to eight mice was allowed to adhere to FBS-precoated Petri dishes for 2-4 h at 37°C. Non-adherent cells were washed off with RPMI. Adherent cells were removed by gentle scraping following incubation in PBS with 0.2% EDTA, 5% FCS for 45 min at 4°C.
T cell culture
For primary stimulation of unseparated splenocyte/LN cell populations, 2.5-5.0X10
6 cells were stimulated in 1 ml cultures in 24-well plates in the presence of varying amounts of OVA protein (0-1000 (ig/ml) and various anti-B7 mAb or isotype controls (20 ng/ml). Unless otherwise indicated, at 48 h, supernatants were harvested for cytokine analysis and the cells were resuspended in IL-2 containing media (5% T-stim). Cells were rested for 10-14 days with fresh IL-2-containing media added every other day. Prior to re-stimulation, the T cells were extensively washed and counted. Where indicated, 
Results
B7-1 and B7-2 levels on freshly isolated splenic APC populations
The APC within the splenocyte population include macrophages, dendritic cells and activated B cells. In order to utilize splenocytes as a source of B7 co-stimulators, it was important to first determine the levels of B7 on the major APC types. In agreement with previous studies (13, 29) , we found little of either B7-1 or B7-2 on the surface of freshly isolated B cells (Fig. 1A) . However, FACS analysis demonstrated both B7-1 and B7-2 expression on a subpopulation of freshly isolated splenic cells. The major source of the B7-1 and B7-2 appeared to be the SAC population. Significant levels of B7-1 and B7-2 were expressed on macrophage and dendritic cells (Fig 1B and C) . Thus, B7-1 and B7-2 were both present on SAC within the stimulation period.
B7-2 is the dominant co-stimulatory ligand in the primary stimulation when whole spleen and LN cells are used
Previous studies which addressed the role of B7 molecules in vitro in the primary response have largely been done with mitogenic or polyclonal stimulation (i.e anti-CD3, alloantigen, superantigen) (5, 7, 8, 13, 30, 31, 38) or B7 transfectants (4, 6, 12, 24, 25) . In order to study a nominal antigen-specific response, we chose to analyze T cell-B7 interactions using spleen cells from the DO11.10TCR-transgenic line. This TCR is specific for OVA peptide (cOVA 323-339) in the context of I-A d . The responses of TCR-transgenic T cells appear similar to those of normal cells and such a system permits analysis of a homogenous antigen-specific, naive T cell population (39) . Furthermore, OVA protein rather than the more commonly used peptide was chosen as the antigen. This should favor presentation by B7 + macrophages and dendritic cells rather than naive B cells. The antigen dose was titrated to 300 ng/ ml, a dose shown to give submaximal proliferation in a secondary stimulation (not shown) in an effort to avoid bypassing the requirement for co-stimulation observed with supra-optimal levels of TCR stimulation.
The primary stimulation was performed with whole spleen/ LN and 300 ug/ml OVA in the presence of saturating amounts (20 ng/ml) of the anti-B7-1 mAb (1G10 or 16-10A1), anti-B7-2 . Naive CD4 + T cells utilize both B7-1 and B7-2 in a primary response As described in Methods, CD45RB h '9 h CD4 + T cells were purified from Tg + mice and stimulated with lightly irradiated (1000 rad), T-cell-depleted splenocytes from non-transgenic BALB/c mice in the presence of the anti-B7 mAb (1G10) or the anti-B7-2 mAb (2D10). Supernatants were harvested on day 4 and assayed for IL-2 by ELISA. This experiment was performed twice with similar results.
(2D10 or GL1), both, or appropriate isotype controls. In supernatants collected 48 h post-stimulation, the cytokines IL-2, IFN-yand GM-CSF were consistently detected. IL-4 was detected at very low levels, near the limit of detection of the ELISA. While the presence of the anti-B7-1 mAb had only a minimal effect on the production of these cytokines, the anti-B7-2 mAb reduced the amount of IL-2, IFN-y ( Fig. 2A) , GM-CSF and IL-4 (not shown) detected by ELISA. This effect was not limited to these particular antibodies as it was reproduced with two additional anti-B7-1 and -2 antibodies, 16-10A1 and GL1 respectively (not shown). In most cases, blocking both B7-1 and B7-2 resulted in a further decrease in the production of these cytokines, demonstrating that B7-1 was functionally present. However, in the primary stimulation of an unfractionated splenocyte/LN population, B7-2 was clearly the more important co-stimulator with respect to cytokme production Interestingly, despite the differences in cytokine production, proliferation at 48 h amongst the groups was very similar at 250 |xg/ml OVA (Fig. 2B) . However, following 10-14 days of rest in the presence of exogenous IL-2, cell recoveries were consistently one-third lower for cells treated with anti-B7-2 or a combination of the anti-B7-antibodies as compared to isotype or anti-B7-1 mAb alone (not shown).
Anti-B7-2 mAb profoundly inhibits the development of T h 2 cells from unfractionated splenocytes
After 10-14 days of resting in IL-2-containing media, restimulation of cells recovered from primary cultures was performed with irradiated, syngeneic splenocytes as APC in the presence or absence of the appropriate anti-B7 antibody There was a substantial decrease in IL-4 ( Fig. 3A) and IL-10 (not shown) production in cultures stimulated in the presence of the anti-B7-2 mAb. It is important to note that the anti-B7-2 mAb did not cause a global ablation of cytokines since IL-2, GM-CSF, (not shown) and IFN-y levels were either equivalent (Fig. 3A) or actually elevated (not shown) in the anti-B7-2-treated groups relative to the control. Furthermore, the anti-B7-2 mAb had only a modest effect on proliferation (Fig. 3B) . Interestingly, anti-B7-2 antibody did not need to be present in the secondary cultures for the reduction in T h 2 cytokines to occur, suggesting that this was not an immediate effect on cytokine synthesis, but rather a perturbation of differentiation that had occurred in the primary culture. If supraoptimal peptide or protein was used, ablation of T h 2 cytokines was not observed (data not shown) consistent with recently published data (40) on the effect of high-dose antigen in promoting T h 2 development.
No effect of the anti-B7-1 antibody on altering Tf, ratios was detected when unseparated spleen cells were used as the (Fig. 4) or LPS-treated spleen cells (not shown) were used as APC for purified CD4 + T cells, an effect of anti-B7-1 in driving T h 2 development could be observed. The FACS profiles of the SAC, shown in Fig. 1 , demonstrated substantial levels of both B7 molecules. While IFN-y production was similar in the presence of the anti-B7-1 or B7-2 mAb, IL-4 levels were significantly increased in the presence of the anti-B7-1 mAb. A third round of stimulation was necessary to reproducibly achieve a significant shift.
Both B7-1 and B7-2 interact with T h p in a primary response
The above experiments utilized unseparated splenocytes as a source of responding T cells although similar results were obtained when purified CD4 cells were used (not shown). Although theoretically, all CD4 + cells from TCR-transgenic mice should be naive, there is a small (<10%) population of CD4 + CD45RB~ cells in mice as young as 8 weeks. Additionally, the presence of IFN-y in culture supernatants of CD8 and NK cell-depleted cultures suggests that memory cells are present. While it could be argued that unseparated spleen actually represents a more biologically relevant population than highly selected T cell subsets, we wished to examine the interaction of the B7 co-stimulators with naive T h p cells in the absence of activated or memory cells. It has been demonstrated that naive and memory cells differ in their dependence on co-stimulation. CD4 + T cells were therefore sorted for CD45RB hl9h expression and used as responders in a primary stimulation with lightly irradiated T cell-depleted spleen as APC. In a primary stimulation, highly purified naive CD45RB h| 9 h T cells produced only IL-2 and little or no IFN-y, consistent with their status as T h p cells. In contrast to the results obtained using an unsorted T cell population, the addition of either the anti-B7-1 or anti-B7-2 antibody alone resulted in a modest, but equivalent, reduction in IL-2 production (Fig. 5) . Both antibodies together dramatically reduced both IL-2 production and cell growth as evidenced by cell recovery at 12 days (not shown). These* experiments demonstrate that Thp cells are highly co-stimulation dependent but can utilize either the B7-1 or B7-2 co-stimulatory molecules.
The B7 co-stimulators differentially drive T h cell development when naive T h p cells are the responder population
After 10-14 days of resting in IL-2-containing media, restimulation of cells recovered from primary cultures of CD45RB high T h p cells was performed with irradiated unactivated (Fig. 6, exp. 1 ) or LPS-treated (Fig. 6, exp. 2) T celldepleted spleen as APC in the presence of the appropriate anti-B7 antibody. As shown in Fig. 6 , inclusion of the anti-B7 antibodies caused substantial and differential shifts in ratios This results in a 72-fold shift in cytokine ratios when treatment with anti-B7-1 and B7-2 mAb is compared. When LPStreated, T cell-depleted splenocytes were used as APC in the secondary stimulation, the differential shift in T h 1/T h 2 cytokine ratios was similar to the results shown although the effect of the anti-B7-1 mAb was less dramatic.
Recombinant IL-4 in the primary stimulation restores T h 2 development in the presence of the anti-B7-2 mAb
The presence of IL-4 during stimulation is known to be important for the development of T h 2 cells (41-43) Thus, the ability of the anti-B7-2 antibody to prevent T h 2 development in the unseparated splenocyte population may have been due to prevention of the release of a critical amount of IL-4 during the primary stimulation necessary for subsequent Th2 cell development. This IL-4 could be made by a small subset of preactivated CD4 + lymphocytes, mast cells or TCR + NK1.1" 1 " cells. Indeed, it has recently been reported that transcripts encoding IL-4 appear as early as 24 h after stimulation in naive T h cultures (44) and we have been able to see low levels of IL-4 protein 48 h after primary stimulation of unfractionated splenocyte populations (not shown). To test the hypothesis that the loss of IL-4 in the primary stimulation accounts for the selective defect in T h 2 development, rlL-4 (1000 U/ml) was added to primary cultures in the presence of anti-B7-2 or control antibodies. In a secondary stimulation it is clear that the addition of rlL-4 indeed circumvented the ablation of T h 2 cytokines by the B7-2 antibody (Fig. 7) .
Thus, the anti-B7-2 mAb appears to function by blocking the production of IL-4 required for T h 2 cell differentiation.
Anti-B7-2 F(ab) fragments block T h 2 development
Although B7-1 and B7-2 share the same counter-receptors, their structural similarity is only modest. In particular, the cytoplasmic domains of B7-1 and B7-2 are markedly different and, hence, could transmit distinct intracellular signals. In fact, there are three potential phosphorylation sites for protein kinase C within the B7-2 cytoplasmic tail (45) . Recent studies have suggested that mAb to the B7 molecules may do more than merely block signal transmission (35) .
To directly test whether the anti-B7-2 antibody was acting as a blocking mAb in our system, an anti-B7-2 F(ab) fragment was included in cultures of whole spleen/LN (Fig. 8) or CD45RB-sorted, naive CD4 + T cells using T-cell-depleted spleen as APC (not shown) In the primary stimulation, the intact anti-B7-2 antibody and the F(ab) fragment had similar effects on IL-2 and IFN-y production (not shown). In the secondary stimulation, both the intact mAb and F(ab) fragment substantially reduced T h 2 cytokines (Fig 8) . Thus, the anti-B7-2 mAb does not appear to exert its effects by cross-linking of the B7-2 molecule.
Discussion
In this study we have examined the ability of the B7-1 and B7-2 co-stimulatory molecules to differentially affect the development of T h 1/T h 2 cell subsets in vitro. The present results indicate that B7-2 preferentially directs highly purified, antigen-specific naive CD4
+ T cells toward a T h 2 phenotype while B7-1 directs T h p cells toward a T h 1 phenotype. The use of physiologic APC rather than B7-transfected cell lines, nominal antigen rather than polyclonal stimulation and naive CD4 + T cells rather than established clones or transformed cells may account for our ability to detect such an effect The in vitro culture system used here may more accurately represent the in vivo situations where anti-B7 mAb have clearly been shown to affect T h cell differentiation.
The composition of the starting responder T cell population affected both the usage of the co-stimulatory molecules in the primary antigen-specific response and their ultimate effect on altering T h subsets as revealed by cytokine profiles in the secondary response. As shown by others, activation of T h p (as defined by a CD4 + CD45RB h ' 9h phenotype) is highly costimulation dependent. In this study, when highly purified, CD4 + CD45RB h ' 9h T cells were used, the interaction of T h p with either the B7-1 or the B7-2 molecules was sufficient since both antibodies were required to suppress proliferation and IL-2 production in a primary response. Neither antibody alone had a detectable effect. However, blocking the interaction of T h p with B7-1 resulted in a different outcome in the secondary stimulation (a T h 2-type cytokine profile) than blocking the T h p/ B7-2 interaction (a T h 1 cytokine profile) These results are consistent with our earlier observations on the effect of anti-B7 antibodies in vivo in EAE (34) .
If, however, unseparated spleen cells or unsorted CD4 + T cells were the responder cells, then B7-2 was clearly the dominant co-stimulator in the primary response, and blocking that interaction led to a substantial reduction in T h 2 cytokine production upon re-stimulation. Indeed, the blockade of Tf,2 development was more pronounced than when purified ThP were used in the primary cultures. We believe these results are best explained by the substantially greater quantities of IFN-y present in cultures initiated with unsorted as compared to highly purified CD45RB hl9h T cells. T h p do not normally produce IFN-y, but in cultures containing unsorted cells, IFN-Y may be produced by the minor population of predifferentiated T cells, NK cells or residual CD8
+ cells. The presence of IFN-y i n the primary response could abrogate the effect of the anti-B7-1 mAb in promoting IL-4 production. Indeed, several studies have shown that the presence of IFN-Y in vivo (46) or in vitro (47, 48) prevents the generation of T h 2 cells Bottomly and colleagues (48) demonstrated that it was necessary to eliminate IFN-Y by using highly purified naive CD4 + T cells to observe the shift toward T h 2 cytokine production with low peptide dose. In our experiments, the effect of IFN-Y could only be overcome by using multiple stimulations with SAC or LPS-activated spleen cells as APC. In these instances, the very high levels of B7-2 on such cells may have synergized with the blockade of B7-1 to favor the T h p/B7-2 interaction and subsequent T h 2 formation. Along the same lines, the presence of IFN-y in the primary response in unsorted as opposed to highly purified T cells likely exacerbated the effect of the B7-2 mAb in reducing T h 2 cytokines. It is unclear which culture system best mirrors biologically relevant events. Indeed, the variable effects noted with administration of anti-B7 antibodies in mouse models of human disease (34, 36) might be explained by differences in the relative predominance of naive and memory T cells or in levels of pre-existing cytokines Early studies suggested that CD28-mediated co-stimulation was more important in the differentiation of T h 1 than T h 2 cells (39, 49, 50) . However, a number of recent studies show that signaling though CD28 is essential for the development of T h 2 cells. Lu era/, demonstrated that CTLA-4-lg administration prevented T cell IL-4 production and subsequent B cell activation and IgE secretion in response to oral infection with the nematode parasite H. polygyrus (51) . Additionally, the susceptibility of BALB/c mice to Leishmania infection could be reversed by early short-term blockade with CTLA-4-lg concomitant with a decrease in levels of IL-4 mRNA in LN cells (52) In the CD28-deficient mouse T h 2-type responses have not been examined directly. However, there is a shift in Ig isotype (a decrease in lgG1 and lgG2b) suggestive of a lack of T h 2 cytokines (16).
In our experiments, the ability of rlL-4 to restore normal T h 2 development in the presence of anti-B7-2 mAb suggests that T h p/B7-2 contact is necessary for an initial release of IL-4 that will prime the system for further IL-4 production. This dependence of IL-4 production on B7-2 has been demonstrated in vitro for human T cells. Freeman et al. (25) demonstrated that B7-1-and B7-2-transfected CHO and NIH 3T3 cells were equally able to stimulate IL-2 and IFN-Y production. However, B7-2 transfectants were better at inducing IL-4 production than B7-1 transfectants with the greatest difference seen when naive CD45RA" 1 " T cells were the responding population. These authors concluded that B7-2 provides an initial signal to induce naive T cells to become IL-4 producers, thereby directing the immune response towards a T h 0/T h 2 phenotype, whereas B7-1 provides a more neutral differentiative signal. Moreover, in a study by Lanier et al. (24) , only B7-2 P815 transfectants could stimulate IL-4 production from small, resting peripheral blood T cells although B7-1 and B7-2 induced IL-2 and IFN-y production equally well. Our use of normal APC populations rather than B7-transfected nonprofessional APC may account for the additional effect of B7-1 on preferentially driving T h 1 development observed in our experiments. Taken together, these data suggest that the priming of T h 2 cells is actually more dependent on the CD28-B7 pathway than that of T h 1 cells and that B7-2, rather than B7-1, is the critical ligand.
The effects of in vivo administration of anti-B7 antibodies could be attributed to blocking of T h p/B7 contact or to cross-linking of B7 itself. The unusual dose-response curve observed by Racke et al. (35) with the combination of intact mAb to B7-1 and B7-2 in contrast to F(ab) fragments or CTLA-4-lg (maximal inhibition at the lowest doses and least inhibition at the highest doses where blocking would occur) is consistent with the latter explanation. Unfortunately, the two mAb were not evaluated separately to determine which of the two mAb was responsible for the effect observed. In the culture system utilized here, the effect of the anti-B7-2 antibody appears to be due to blockade since the F(ab) fragment also ablates T h 2 cytokine production. We cannot distinguish, at the moment, however, between these two possibilities for the B7-1 antibody, although we were unable to detect evidence of cross-linking as assessed by triggering of APC-derived cytokines such as IL-12 (A. M. Ranger, unpublished data) Given the different structures of the B7-1 and B7-2 proteins, especially in the organization of the cytoplasmic domain, it is of course possible that the antibodies exert their effects through different mechanisms.
Several models have recently been proposed to explain the differential effect of B7-1 and B7-2 in affecting T h cell development. Engagement of CD28/CTLA-4 receptors with their B7 ligands may result in the transmission of distinct intracytoplasmic signals. However, in initial experiments comparing patterns of proteins undergoing phosphorylation at tyrosine residues in response to blocking B7-1 or B7-2, we have been unable to find evidence for such differential signaling at the level of the T h p cell (A. M. Ranger, unpublished data). A second model invokes differential signaling into the APC by cross-linking of B7 surface antigens. The intracellular signals transmitted might differentially regulate the production of cytokines, such as IL-12 and IL-10 known to drive T h cell development Antibodies to MHC class II and B7 molecules, or to B7 molecules alone were added to T-depleted splenocyte cultures. Assays to detect IL-12, IL-10 and TNF-a, however, failed to reveal any of these cytokines in culture supernatants (not shown). Further, IL-12 could not be detected in primary or secondary TCR-transgenic cultures even when SAC were used as APC, a situation where IL-12 should be maximal. Thus, unless these cytokines are readily consumed or are structurally altered, they are probably not responsible for the shift in T h subsets observed. Alternatively, there may be other differentiation factors that account for the B7-mediated alterations in T h cell differentiation. For example, the newly discovered IFN-y-inducing factor, secreted by activated murine macrophages, is more potent than IL-12 at eliciting IFN-y production from T cells (53) and human T cells have at least two cell surface molecules, SLAM and CD82, which have recently been reported to enhance IFN-y, but not IL-4 production upon engagement (54, 55) . If this were the case, use of CHO or L cell B7 transfectants or B cells as APC in stimulation protocols would not be expected to result in differential T h 1 or T h 2 development.
A third model, termed the 'strength of signal' hypothesis (56, 57) , suggests that a low signal intensity enhances the development of T h 1 cells while higher signal intensity favors T h 2 cell formation This model, originally proposed in 1974 (58) , has recently gained additional support from experiments using TCR-transgenic T cells where peptide dose determined the relative predominance of IL-4 or IFN-y (40) . According to this model, in the TCR-transgenic culture system utilized in our experiments, blocking B7-2 would result in a 'low intensity' stimulation, favoring T^J cell formation. In our system, both B7-1 and B7-2 are present on freshly isolated adherent cells (Fig. 1) . However, levels of B7-2 increase more rapidly than B7-1 during the culture period (not shown). It is possible that when the B7-2 molecule is blocked, B7-1 levels are insufficient to drive T h 2 development. In fact, in stimulation protocols where B7-1 is rapidly up-regulated (LPS-activated APC), the shift in the T h 1/T h 2 cytokine ratio is less extreme (A. M. Ranger, unpublished data). Alternatively, the interaction with B7-1 may be inhibitory. Indeed, forced expression of B7-1 on mature B cells in transgenic mice depressed the antibody response to hapten-protein conjugates, suggesting that B7-1 contributed to feedback inhibition of T cell-dependent immune responses in vivo (59) . This signal may be transmitted by binding of CTLA-4 to B7-1, an interaction which is of higher affinity than its binding to B7-2. By blocking this interaction with anti-B7-1 antibody, the stimulation period may have been extended or the balance between negative and positive signals shifted such that a T h 2 state was achieved much as it is with increased peptide dose. In fact, in situations where the most dramatic T h 2 shift was achieved with the anti-B7-1 mAb (see Fig. 4 , exp. 1), there were -30% more cells in the anti-B7-1 -treated group compared to the control (A. M. Ranger, unpublished observations). Finally, a fourth possibility is that the timing of expression of the co-stimulatory molecules accounts for their differential effects. If early activation of the CD28 pathway results in an initial release of IL-4, then the earlier expression of B7-2 than B7-1 in culture might result in a skewing to a T h 2 pathway. This model would predict that forced early expression of B7-1 would also result in T h 2 development. Our results can potentially be explained by any one of the suggested models: indeed, these models are not necessarily mutually exclusive. Further work will be required to firmly establish the molecular basis for the differential effect of the B7 co-stimulatory molecules on T h cell development. 
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